MedTrace Logo

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

NCT00937664 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-02-07

No results posted yet for this study

Summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.

Conditions

Interventions

DRUG

AZD7762

solution, intravenous, weekly

DRUG

gemcitabine

intravenous, weekly

Sponsors & Collaborators

Principal Investigators

  • Peter Langmuir, MD · AstraZeneca

  • Takashi Seto, MD, PhD · National Hospital Organization Kyushu Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00937664 on ClinicalTrials.gov